Management of hyperuricemia in adults with or at risk of tumor lysis syndrome

ABOUT THE AUTHORS

Affiliations: Dr. Seiter is Professor of Medicine and Director of the Leukemia Service at New York Medical College, Valhalla, NY. Dr. Sarlis is currently Vice President and Head of the Medical Affairs Department at Incyte Corporation, Wilmington, DE. Dr. Kim is Associate Professor and Chief, Section of Head and Neck Medical Oncology, Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, Houston, TX.

Conflicts of interest: Dr. Sarlis was an employee of sanofi-aventis U.S. at the time this article was written and holds stock options and stock in this company. Drs. Seiter and Kim have no pertinent conflicts of interest to disclose.

Karen P. Seiter, MD,¹ Nicholas J. Sarlis, MD, PhD, FACP,^2* and Edward S. Kim, MD³

1. New York Medical College, Valhalla, NY;
2. Medical Affairs–Oncology, sanofi-aventis U.S., Bridgewater, NJ; and
3. The University of Texas MD Anderson Cancer Center, Houston, TX